BACL®7G | Complete the draft participation form

A · Prospective holder identification

The prospective holder is the PF/PJ in whose name the units will be registered. References: CPM Rules V10, sections 2.1 and 2.3.

A.1 · Prospective holder type

A.2 · Full name of the PF or registered name of the PJ

A.3 · Country of residence or registered office

A.3f · Country of tax residence

A.4 · CPF of the PF or CNPJ of the PJ; foreign applicants: type, number and issuing country of the local equivalent

A.5 · Official email for this request

A.5t · Contact phone number (optional)

A.6 · In what capacity are you completing this form?

A.7 · Legal capacity or representation required by the applicable instrument and country

B · Relationships with companies and groups

Employment, provision of services, passive minority ownership, family relationships or operating in the same sector are not, on their own, sufficient to aggregate purchases within a group. BACL®7G will assess actual control and conduct. References: sections 1.3, 2.2 and 2.4.

B.1 · Do you have a relationship with any company or entity?

B.3 · Identify each relevant entity and your relationship with itFor each entity: name, country, role and nature of the relationship. Provide the registration identifier, equity interest and voting rights when necessary to assess control or representation.

B.4 · Does the company or entity belong to a group or corporation?

B.5 · Group name and known parent company; if unknown, explain

B.6 · Does any of these relationships influence the decision, benefit or funding of this participation?

B.6d · Explain the influence, if any or if clarification is pending

C · Representation and authority

Complete only if there is representation. Identify all representatives whose action or signature is required. Representation will be checked before an authorization key is issued; the representative does not become the prospective holder of the units. References: sections 2.3 and 2.6.

C.1 · Are you acting as a representative in this request?

Not applicable; I am acting on my own behalf

C.2 · Representative's name and applicable identification

C.3 · PF/PJ represented and relationship with the prospective holder identified in A.2

C.4 · Role and source of authority

C.4d · Explain the source of authority

C.5 · Instrument or power of attorney: issuer, date, validity and attachment code

C.6 · Limits on participating, signing and paying; joint signature and other signatories

C.7 · Does the authority cover this quantity and this round?

C.7d · Additional information about authority

D · Control and ultimate beneficial owner

It will not be assumed that every equity interest or funding relationship constitutes common control. The organizational chart and relevant documents will be submitted through the future formal channel, with their date and source. References: sections 1.2, 1.3, 2.3 and 2.4.

D.1 · Does the prospective holder control, or is the prospective holder controlled by, another person or entity?

D.2 · Describe the ownership chain and relevant controlFor each link: entity or person, country, identifier, equity interest, voting rights and basis of control. Include holding companies, foreign subsidiaries and agreements. Identify the natural persons at the end of the chain or explain the structure if no controlling party is identified.

D.3 · Name of the declared group or control bloc and its relevant members

D.4 · Who decides on this participation and who will receive the economic benefit?

D.5 · Who will fund the transaction and what is their relationship with the prospective holder?

D.6 · Are you acting on behalf of or under the direction of a third party, other than the representative already identified?

D.6d · Identify the third party or explain the pending information

E · Request and review by round

Complete for review; no round is open through this form. The planned cap is 280,000 units per prospective holder and, in aggregate, per group under common control, in each round. Do not add different rounds together or count an authorization converted into units twice. References: sections 1.2, 1.4, 2.5 and 2.9.

E.1 · Reference round (planned)

E.1d · Reference date

E.2 · Number of units requested

E.3 · Units already acquired by the prospective holder in this same round

E.4 · Requests under review and still-valid keys held by the prospective holder in this round State the quantity and reference number of each record, zero, or any information requiring clarification.

E.5 · Units, requests and keys of members of the same control bloc in this round State the prospective holder, quantity and reference number; declare zero or any information requiring clarification.

E.6 · Does this request replace or amend a previous request? State its reference number and the change

E.7 · Relevant relationship or conflict of interest not disclosed in previous answers

F · Applicant's documents and declarations

These declarations belong to the future formal process. Self-declaration forms part of the documentary review and does not, on its own, establish the facts. References: sections 2.6, 2.7, 2.8, 2.10, 4.1, 4.2 and 12.4.

F.1 · List of attachments required for this caseList the code, type, prospective holder or entity, date/validity and source. Examples: identification, PJ registration, corporate instruments, ownership chain and control agreements, representative authority. Do not submit documents at this stage.

F.2 · I declare that the answers and relevant relationships disclosed are true and complete in accordance with the documents presented.

F.3 · I declare the identity of the true prospective holder, on whose behalf I act, and the relevant members of the control bloc. I am not using this request to multiply the cap through companies or nominees.

F.4 · I undertake to disclose relevant changes as soon as I become aware of them and before any new authorization or payment, in accordance with section 2.7.

F.5 · I acknowledge the cap per round and the need for validation and an authorization key before payment.

F.6 · I acknowledge the prohibition on trading in secondary or over-the-counter markets, whether organized or not, until the actual start of worldwide-scale production, planned for 30/12/2033. The planned date alone does not permit trading or exchanges.

F.7 · I acknowledge that all reports evidencing the execution of each round, from CPM-01 to CPM-12, will undergo an INDEPENDENT AUDIT before final validation.

F.8 · Reference versions

Draft V4 · CPM Rules V10 · Multilingual form dated 16/10/2026.

F.9 · Name of the prospective holder and representative, if any, for checking the draft The name entered in this preparation is neither a signature nor authenticated acceptance. The date and time zone will be included in the review.

Draft participation form